The DOI matches its Crossref record; 168 of the 168 references it cites were found in a registry or an index.
Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches
Open accessAbstract
Prostate cancer is one of the malignancies that affects men and significantly contributes to increased mortality rates in men globally. Patients affected with prostate cancer present with either a localized or advanced disease. In this review, we aim to provide a holistic overview of prostate cancer, including the diagnosis of the disease, mutations leading to the onset and progression of the disease, and treatment options. Prostate cancer diagnoses include a digital rectal examination, prostate-specific antigen analysis, and prostate biopsies. Mutations in certain genes are linked to the onset, progression, and metastasis of the cancer. Treatment for localized prostate cancer encompasses active surveillance, ablative radiotherapy, and radical prostatectomy. Men who relapse or present metastatic prostate cancer receive androgen deprivation therapy (ADT), salvage radiotherapy, and chemotherapy. Currently, available treatment options are more effective when used as combination therapy; however, despite available treatment options, prostate cancer remains to be incurable. There has been ongoing research on finding and identifying other treatment approaches such as the use of traditional medicine, the application of nanotechnologies, and gene therapy to combat prostate cancer, drug resistance, as well as to reduce the adverse effects that come with current treatment options. In this article, we summarize the genes involved in prostate cancer, available treatment options, and current research on alternative treatment options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
EAU Guidelines on Prostate Cancer
Heidenreich, A., Aus, G., Bolla, M., Joniau, S., Matveev, V. B., Schmid, H. P., & Zattoni, F. (2008) · European Urology · doi:10.1016/j.eururo.2007.09.002 · Cited by 3,136
MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis
Kasivisvanathan, V., Rannikko, A. S., Borghi, M., Panebianco, V., Mynderse, L. A., Vaarala, M. H., Briganti, A., Budäus, L., Hellawell, G., Hindley, R. G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801993 · Cited by 3,091
Cancer and Radiation Therapy: Current Advances and Future Directions
Baskar, R., Lee, K. A., Yeo, R., & Yeoh, K.-W. (2012) · International Journal of Medical Sciences · doi:10.7150/ijms.3635 · Cited by 2,880
Epidemiology of Prostate Cancer
Rawla, P. (2019) · World Journal of Oncology · doi:10.14740/wjon1191 · Cited by 2,776
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710
Estimates of cancer incidence and mortality in Europe in 2008
Ferlay, J., Parkin, D. M., & Steliarova-Foucher, E. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2009.12.014 · Cited by 2,319
Inflammation in prostate carcinogenesis
De Marzo, A. M., Platz, E. A., Sutcliffe, S., Xu, J., Grönberg, H., Drake, C. G., Nakai, Y., Isaacs, W. B., & Nelson, W. G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2090 · Cited by 1,621
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Watson, P. A., Arora, V. K., & Sawyers, C. L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4016 · Cited by 1,536
Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance
Yao, Y., Zhou, Y., Liu, L., Xu, Y., Chen, Q., Wang, Y., Wu, S., Deng, Y., Zhang, J., & Shao, A. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00193 · Cited by 1,451
Molecular genetics of prostate cancer: new prospects for old challenges
Shen, M. M., & Abate-Shen, C. (2010) · Genes & Development · doi:10.1101/gad.1965810 · Cited by 946
EZH2: a novel target for cancer treatment
Duan, R., Du, W., & Guo, W. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00937-8 · Cited by 926
Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics
Jan, R., & Chaudhry, G.-E.-S. (2019) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2019.024 · Cited by 899
mtDNA mutations increase tumorigenicity in prostate cancer
Petros, J. A., Baumann, A. K., Ruiz-Pesini, E., Amin, M. B., Sun, C. Q., Hall, J., Lim, S., Issa, M. M., Flanders, W. D., Hosseini, S. H., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408894102 · Cited by 836
Ras history: The saga continues
Cox, A. D., & Der, C. J. (2010) · Small GTPases · doi:10.4161/sgtp.1.1.12178 · Cited by 706
Plant-derived anticancer agents: A green anticancer approach
Iqbal, J., Abbasi, B. A., Mahmood, T., Kanwal, S., Ali, B., Shah, S. A., & Khalil, A. T. (2017) · Asian Pacific Journal of Tropical Biomedicine · doi:10.1016/j.apjtb.2017.10.016 · Cited by 685
Clinical implications of PTEN loss in prostate cancer
Jamaspishvili, T., Berman, D. M., Ross, A. E., Scher, H. I., De Marzo, A. M., Squire, J. A., & Lotan, T. L. (2018) · Nature Reviews Urology · doi:10.1038/nrurol.2018.9 · Cited by 651
CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy
Rosenblum, D., Gutkin, A., Kedmi, R., Ramishetti, S., Veiga, N., Jacobi, A. M., Schubert, M. S., Friedmann-Morvinski, D., Cohen, Z. R., Behlke, M. A., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc9450 · Cited by 614
Precision medicine for cancer with next-generation functional diagnostics
Friedman, A. A., Letai, A., Fisher, D. E., & Flaherty, K. T. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4015 · Cited by 570
The role of microRNAs in human diseases
Tüfekci, K. U., Öner, M. G., Meuwissen, R. L. J., & Genç, Ş. (2014) · Methods in molecular biology · doi:10.1007/978-1-62703-748-8_3 · Cited by 566
Scavenger Receptors in Atherosclerosis: Beyond Lipid Uptake
Moore, K. J., & Freeman, M. W. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000229218.97976.43 · Cited by 562
Steelman, L. S., Chappell, W. H., Abrams, S. L., Kempf, C. R., Long, J., Laidler, P., Mijatovic, S., Maksimovic-Ivanic, D., Stivala, F., Mazzarino, M. C., et al. (2011) · Aging · doi:10.18632/aging.100296 · Cited by 553
Neuroprotective potential of phytochemicals
Kumar, G., & Khanum, F. (2012) · Pharmacognosy Reviews · doi:10.4103/0973-7847.99898 · Cited by 511
Potosky, A. L. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.19.1582 · Cited by 510
A continuum model for tumour suppression
Berger, A. H., Knudson, A. G., & Pandolfi, P. P. (2011) · Nature · doi:10.1038/nature10275 · Cited by 501
Targeted therapy using nanotechnology: focus on cancer
Sechi, M., Sanna, V., & Pala, N. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s36654 · Cited by 493
Magnetic nanoparticle hyperthermia for prostate cancer
Johannsen, M., Thiesen, B., Wust, P., & Jordan, A. (2010) · International Journal of Hyperthermia · doi:10.3109/02656731003745740 · Cited by 469
Taitt, H. E. (2018) · American Journal of Men's Health · doi:10.1177/1557988318798279 · Cited by 463
Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification
Kamps, R., Brandão, R., Bosch, B., Paulussen, A., Xanthoulea, S., Blok, M., & Romano, A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020308 · Cited by 453
Mitochondrial DNA in human malignancy
Penta, J. S., Johnson, F. M., Wachsman, J. T., & Copeland, W. C. (2001) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(01)00053-9 · Cited by 441
Loss of ERβ expression as a common step in estrogen-dependent tumor progression
Bardin, A., Boulle, N., Lazennec, G., Vignon, F., & Pujol, P. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00800 · Cited by 417
Herbal plants and their derivatives as growth and health promoters in animal nutrition
Hashemi, S. R., & Davoodi, H. (2011) · Veterinary Research Communications · doi:10.1007/s11259-010-9458-2 · Cited by 403
Seidenfeld, J., Samson, D. J., Hasselblad, V., Aronson, N., Albertsen, P. C., Bennett, C. L., & Wilt, T. J. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-7-200004040-00009 · Cited by 398
The worldwide epidemiology of prostate cancer: perspectives from autopsy studies.
Haas, G. P., Delongchamps, N. B., Brawley, O. W., Wang, C. Y., & de la Roza, G. (2008) · PubMed · Cited by 365
The Smart Targeting of Nanoparticles
Friedman, A., Claypool, S., & Liu, R. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990375 · Cited by 364
Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001
DeVore, N. M., & Scott, E. E. (2012) · Nature · doi:10.1038/nature10743 · Cited by 341
Diverse Mechanisms of Somatic Structural Variations in Human Cancer Genomes
Yang, L., Luquette, L. J., Gehlenborg, N., Xi, R., Haseley, P. S., Hsieh, C.-H., Zhang, C., Ren, X., Protopopov, A., Chin, L., et al. (2013) · Cell · doi:10.1016/j.cell.2013.04.010 · Cited by 337
Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations
Moran, A., O’Hara, C., Khan, S., Shack, L., Woodward, E., Maher, E. R., Lalloo, F., & Evans, D. G. R. (2012) · Familial Cancer · doi:10.1007/s10689-011-9506-2 · Cited by 307
Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer
Gallagher, D. J., Gaudet, M. M., Pal, P., Kirchhoff, T., Balistreri, L., Vora, K., Bhatia, J., Stadler, Z., Fine, S. W., Reuter, V., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2871 · Cited by 301
Chen, Y., Chi, P., Rockowitz, S., Iaquinta, P. J., Shamu, T., Shukla, S., Gao, D., Sirota, I., Carver, B. S., Wongvipat, J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3216 · Cited by 282
Castration-Resistant Prostate Cancer: AUA Guideline
Cookson, M. S., Roth, B. J., Dahm, P., Engstrom, C., Freedland, S. J., Hussain, M., Lin, D. W., Lowrance, W. T., Murad, M. H., Oh, W. K., et al. (2013) · Journal of Urology · doi:10.1016/j.juro.2013.05.005 · Cited by 275
Autio, K. A., Dreicer, R., Anderson, J., Garcia, J. A., Alva, A., Hart, L. L., Milowsky, M. I., Posadas, E. M., Ryan, C. J., Graf, R. P., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2168 · Cited by 275
Alternative splicing: an emerging topic in molecular and clinical oncology
Pajares, M. J., Ezponda, T., Catena, R., Calvo, A., Pio, R., & Montuenga, L. M. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70104-3 · Cited by 267
Androgen Receptor Splice Variants Determine Taxane Sensitivity in Prostate Cancer
Thadani-Mulero, M., Portella, L., Sun, S., Sung, M., Matov, A., Vessella, R. L., Corey, E., Nanus, D. M., Plymate, S. R., & Giannakakou, P. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2876 · Cited by 256
The Heritability of Prostate Cancer in the Nordic Twin Study of Cancer
Hjelmborg, J. B., Scheike, T., Holst, K., Skytthe, A., Penney, K. L., Graff, R. E., Pukkala, E., Christensen, K., Adami, H.-O., Holm, N. V., et al. (2014) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0568 · Cited by 252
Regulation of prostate cancer progression by the tumor microenvironment
Shiao, S. L., Chu, G. C.-Y., & Chung, L. W. K. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.12.022 · Cited by 241
The Mutational Landscape of Prostate Cancer
Barbieri, C. E., Bangma, C. H., Bjartell, A., Catto, J. W. F., Culig, Z., Grönberg, H., Luo, J., Visakorpi, T., & Rubin, M. A. (2013) · European Urology · doi:10.1016/j.eururo.2013.05.029 · Cited by 239
Gurel, B., Lucia, M. S., Thompson, I. M., Goodman, P. J., Tangen, C. M., Kristal, A. R., Parnes, H. L., Hoque, A., Lippman, S. M., Sutcliffe, S., et al. (2014) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-1126 · Cited by 236
Personalized medicine using DNA biomarkers: a review
Ziegler, A., Koch, A., Krockenberger, K., & Großhennig, A. (2012) · Human Genetics · doi:10.1007/s00439-012-1188-9 · Cited by 213
Drug Repurposing (DR): An Emerging Approach in Drug Discovery
Rudrapal, M., J. Khairnar, S., & G. Jadhav, A. (2020) · Drug Repurposing - Hypothesis, Molecular Aspects and Therapeutic Applications · doi:10.5772/intechopen.93193 · Cited by 207
Cytochrome P 450 1B1 Is Overexpressed and Regulated by Hypomethylation in Prostate Cancer
Tokizane, T., Shiina, H., Igawa, M., Enokida, H., Urakami, S., Kawakami, T., Ogishima, T., Okino, S. T., Li, L.-C., Tanaka, Y., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2545 · Cited by 202
Human CYP1B1 and Anticancer Agent Metabolism: Mechanism for Tumor-Specific Drug Inactivation?
Rochat, B., Morsman, J. M., Murray, G. I., Figg, W. D., & McLeod, H. L. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38762-2 · Cited by 200
Metallic nanoparticles as drug delivery system for the treatment of cancer
Desai, N., Momin, M., Khan, T., Gharat, S., Ningthoujam, R. S., & Omri, A. (2021) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1912008 · Cited by 197
Crawford, E. D., Higano, C. S., Shore, N. D., Hussain, M., & Petrylak, D. P. (2015) · Journal of Urology · doi:10.1016/j.juro.2015.06.106 · Cited by 190
Delivery and Specificity of CRISPR/Cas9 Genome Editing Technologies for Human Gene Therapy
Gori, J. L., Hsu, P. D., Maeder, M. L., Shen, S., Welstead, G. G., & Bumcrot, D. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.074 · Cited by 189
Suzuki, T., Li, W., Zhang, Q., Karim, A., Novak, E. K., Sviderskaya, E. V., Hill, S. P., Bennett, D. C., Levin, A. V., Nieuwenhuis, H. K., et al. (2002) · Nature Genetics · doi:10.1038/ng835 · Cited by 187
Androgens and androgen receptor signaling in prostate tumorigenesis
Zhou, Y., Bolton, E. C., & Jones, J. O. (2015) · Journal of Molecular Endocrinology · doi:10.1530/jme-14-0203 · Cited by 183
Bonkhoff, H. (2018) · The Prostate · doi:10.1002/pros.23446 · Cited by 183
Okaiyeto, K., & Oguntibeju, O. O. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18115988 · Cited by 182
Implications for RNase L in Prostate Cancer Biology
Silverman, R. H. (2003) · Biochemistry · doi:10.1021/bi027147i · Cited by 177
Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer
Sun, X., Frierson, H. F., Chen, C., Li, C., Ran, Q., Otto, K. B., Cantarel, B. M., Vessella, R. L., Gao, A. C., Petros, J., et al. (2005) · Nature Genetics · doi:10.1038/ng1528 · Cited by 174
The role of BRCA1 and BRCA2 in prostate cancer
Castro, E., & Eeles, R. (2012) · Asian Journal of Andrology · doi:10.1038/aja.2011.150 · Cited by 170
Epidemiology of Prostate Cancer
Bashir, M. N. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.13.5137 · Cited by 168
Medicinal plants commonly used against cancer in traditional medicine formulae in Sri Lanka
Kuruppu, A. I., Paranagama, P. A., & Goonasekara, C. L. (2019) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2019.02.004 · Cited by 162
Overcoming docetaxel resistance in prostate cancer: a perspective review
Hwang, C. (2012) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834012449685 · Cited by 161
Curcumin against Prostate Cancer: Current Evidence
Termini, D., Den Hartogh, D. J., Jaglanian, A., & Tsiani, E. (2020) · Biomolecules · doi:10.3390/biom10111536 · Cited by 161
Aromatase and regulating the estrogen:androgen ratio in the prostate gland
Ellem, S. J., & Risbridger, G. P. (2010) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2009.10.015 · Cited by 160
Drug discovery in advanced prostate cancer: translating biology into therapy
Yap, T. A., Smith, A. D., Ferraldeschi, R., Al‐Lazikani, B., Workman, P., & Bono, J. S. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.120 · Cited by 157
Viral Vectors for Gene Transfer
Chen, Y. H., Keiser, M. S., & Davidson, B. L. (2018) · Current Protocols in Mouse Biology · doi:10.1002/cpmo.58 · Cited by 146
Dunn, M. W., & Kazer, M. W. (2011) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2011.07.002 · Cited by 146
The androgen/androgen receptor axis in prostate cancer
Bluemn, E. G., & Nelson, P. S. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32835105b3 · Cited by 145
Fraser, M. E., Zhao, H. W., Luoto, K. R., Lundin, C., Coackley, C. L., Chan, N. H. L., Joshua, A. M., Bismar, T. A., Evans, A. J., Helleday, T., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2189 · Cited by 138
Lima, Z. S., Ghadamzadeh, M., Arashloo, F. T., Amjad, G., Ebadi, M. R., & Younesi, L. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0725-6 · Cited by 136
Estrogens and Their Receptors in Prostate Cancer: Therapeutic Implications
Zazzo, E. D., Galasso, G., Giovannelli, P., Donato, M. D., & Castoria, G. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00002 · Cited by 132
Inhibition of ABCB1 Expression Overcomes Acquired Docetaxel Resistance in Prostate Cancer
Zhu, Y., Liu, C., Nadiminty, N., Lou, W., Tummala, R., Evans, C. P., & Gao, A. C. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0208 · Cited by 130
Regulation of TGFβ in the immune system: An emerging role for integrins and dendritic cells
Worthington, J. J., Fenton, T. M., Czajkowska, B. I., Klementowicz, J. E., & Travis, M. A. (2012) · Immunobiology · doi:10.1016/j.imbio.2012.06.009 · Cited by 129
Estrogen Receptor β as a Pharmaceutical Target
Warner, M. N., Huang, B., & Gustafsson, J.-Α. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.10.006 · Cited by 128
Prostate cancer risk prediction based on complete prostate cancer family history
Albright, F. S., Stephenson, R. A., Agarwal, N., Teerlink, C. C., Lowrance, W. T., Farnham, J. M., & Cannon‐Albright, L. (2014) · The Prostate · doi:10.1002/pros.22925 · Cited by 127
Drug Repositioning for Effective Prostate Cancer Treatment
Turanlı, B., Grøtli, M., Borén, J., Nielsen, J., Uhlén, M., Arğa, K. Y., & Mardinoğlu, A. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00500 · Cited by 125
Guarini, A. R., Marinelli, M., Tavolaro, S., Bellacchio, E., Magliozzi, M., Chiaretti, S., Propris, M. S. D., Peragine, N., Santangelo, S., Paoloni, F. P., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.049270 · Cited by 121
KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis
Narla, G., DiFeo, A. V., Fernández, Y., Dhanasekaran, S. M., Huang, F., Sangodkar, J., Hod, E. A., Leake, D., Friedman, S. L., Hall, S. J., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34780 · Cited by 119
Therapeutic Approaches Targeting MYC-Driven Prostate Cancer
Rebello, R. J., Pearson, R. B., Hannan, R. D., & Furic, L. (2017) · Genes · doi:10.3390/genes8020071 · Cited by 118
Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review
Lamy, P., Allory, Y., Gauchez, A., Asselain, B. J. R., Beuzeboc, P., de Crémoux, P., Fontugne, J., Georges, A., Hennequin, C., Lehmann‐Che, J., et al. (2017) · European Urology Focus · doi:10.1016/j.euf.2017.02.017 · Cited by 117
Molina, A., & Belldegrun, A. (2011) · Journal of Urology · doi:10.1016/j.juro.2010.10.042 · Cited by 112
Abidi, A. (2013) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.119704 · Cited by 107
The Use of Biomarkers in Prostate Cancer Screening and Treatment.
Alford, A. V., Brito, J. M., Yadav, K. K., Yadav, S. S., Tewari, A. K., & Renzulli, J. (2017) · PubMed · doi:10.3909/riu0772 · Cited by 107
Wen, S., Chang, H., Tian, J., Shang, Z., Niu, Y., & Chang, C. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.10.012 · Cited by 106
Apoptosis and Pharmacological Therapies for Targeting Thereof for Cancer Therapeutics
Singh, V., Khurana, A., Navik, U., Allawadhi, P., Bharani, K. K., & Weiskirchen, R. (2022) · Sci · doi:10.3390/sci4020015 · Cited by 106
Palop, J. J., Mucke, L., & Roberson, E. D. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-744-0_17 · Cited by 105
Paraoxonase 1 in neurological disorders
Menini, T., & Gugliucci, A. (2013) · Redox Report · doi:10.1179/1351000213y.0000000071 · Cited by 105
Chopra, S., Foltz, W. D., Milosevic, M., Toi, A., Bristow, R. G., Ménard, C. M., & Haider, M. A. (2009) · International Journal of Radiation Biology · doi:10.1080/09553000903043059 · Cited by 103
Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy
Braga‐Basaria, M., Muller, D. C., Carducci, M. A., Dobs, A. S., & Basaria, S. S. (2006) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3901471 · Cited by 101
Prostate Cancer Radiogenomics—From Imaging to Molecular Characterization
Ferro, M., COBELLI, O. D., Vartolomei, M. D., Lucarelli, G. T., Crocetto, F., Barone, B., Sciarra, A., Giudice, F. D., Muto, M., Maggi, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189971 · Cited by 97
Takayama, K. (2019) · Biomolecules · doi:10.3390/biom9040131 · Cited by 94
Slavin, D. A., Koritschoner, N. P., Prieto, C. C., López-Díaz, F. J., Chatton, B., & Bocco, J. L. (2004) · Oncogene · doi:10.1038/sj.onc.1208020 · Cited by 92
Advances in prostate cancer treatment
Trewartha, D., & Carter, K. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4068 · Cited by 91
Urinary biomarkers for prostate cancer: a review
Hessels, D., & Schalken, J. A. (2013) · Asian Journal of Andrology · doi:10.1038/aja.2013.6 · Cited by 88
Chen, J., Zhang, D., Yan, W., Yang, D., & Shen, B. (2013) · BioMed Research International · doi:10.1155/2013/901578 · Cited by 87
The Role of Estrogen Receptor β in Prostate Cancer
Christoforou, P., CHRISTOPOULOS, P. F., & Koutsilieris, M. (2014) · Molecular Medicine · doi:10.2119/molmed.2014.00105 · Cited by 87
Modern biomarkers in prostate cancer diagnosis
Porzycki, P., & Ciszkowicz, E. (2020) · Editor-in-Chief s Voice List of Authors is an Important Element in a Scientific Publication · doi:10.5173/ceju.2020.0067r · Cited by 87
Brogden, R. N., & Chrisp, P. (1991) · Drugs & Aging · doi:10.2165/00002512-199101020-00003 · Cited by 86
Personalised medicine for cancer: from drug development into clinical practice
Jain, K. K. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.9.1463 · Cited by 82
Flutamide: An Antiandrogen for Advanced Prostate Cancer
Goldspiel, B. R., & Köhler, D. (1990) · DICP · doi:10.1177/106002809002400612 · Cited by 77
Hussein, M.-R. A., Al-Assiri, M., & Musalam, A. O. (2008) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2008.11.010 · Cited by 76
Matowa, P. R., Gundidza, M., Gwanzura, L., & Nhachi, C. F. B. (2020) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-020-03046-8 · Cited by 74
Genetic variation in RNASEL associated with prostate cancer risk and progression
Meyer, M. S., Penney, K. L., Rider, J. R., Schumacher, F. R., Sesso, H. D., Loda, M. F., Fiorentino, M., Finn, S. P., Flavin, R., Kurth, T., et al. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq132 · Cited by 71
CRISPR/Cas9 targeting of GPRC6A suppresses prostate cancer tumorigenesis in a human xenograft model
Ye, R.-S., Pi, M., Cox, J. V., Nishimoto, S. K., & Quarles, L. D. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0561-x · Cited by 68
Crocetto, F., Zazzo, E. D., Buonerba, C., Aveta, A., Pandolfo, S. D., Barone, B., Trama, F., Caputo, V. F., Scafuri, L., Ferro, M., et al. (2021) · Nutrients · doi:10.3390/nu13113750 · Cited by 68
The Stroma—A Key Regulator in Prostate Function and Malignancy
Hägglöf, C., & Bergh, A. R. J. (2012) · Cancers · doi:10.3390/cancers4020531 · Cited by 67
Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
Stein, M., Patel, N., Bershadskiy, A., Sokoloff, A., & Singer, E. A. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.129133 · Cited by 67
The status of surgery in the management of high-risk prostate cancer
Bach, C. M., Pisipati, S., Daneshwar, D., Wright, M., Rowe, E., Gillatt, D. A., Persad, R. A., & Koupparis, A. J. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.100 · Cited by 65
Reviews Signalling pathways in endometrial cancer
Markowska, A., Pawałowska, M., Lubin, J., & Markowska, J. (2014) · Współczesna Onkologia · doi:10.5114/wo.2014.43154 · Cited by 64
Bardis, M. D., Houshyar, R., Chang, P., Ushinsky, A., Glavis‐Bloom, J., Chahine, C., Bui, T., Rupasinghe, M., Filippi, C. G., & Chow, D. S. (2020) · Cancers · doi:10.3390/cancers12051204 · Cited by 64
Targeting Cancer with CRISPR/Cas9-Based Therapy
Balon, K., Sheriff, A., Jackow, J., & Łaczmański, Ł. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23010573 · Cited by 63
Miyake, H., Hara, I., & Eto, H. (2005) · British Journal of Urology · doi:10.1111/j.1464-410x.2005.05766.x · Cited by 61
Genetic testing in prostate cancer management: Considerations informing primary care
Giri, V. N., Morgan, T. M., Morris, D. S., Berchuck, J. E., Hyatt, C., & Taplin, M. (2022) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21720 · Cited by 61
Docetaxel and Doxorubicin Codelivery by Nanocarriers for Synergistic Treatment of Prostate Cancer
Li, K., Zhan, W., Chen, Y., Jha, R. K., & Chen, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01436 · Cited by 59
Takizawa, I., Lawrence, M. G., Balanathan, P., Rebello, R. J., Pearson, H. B., Garg, E., Pedersen, J., Pouliot, N., Nadon, R., Watt, M. J., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2820 · Cited by 57
Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform
Gillessen, S., Gilson, C., James, N. D., Adler, A., Sydes, M. R., & Clarke, N. W. (2016) · European Urology · doi:10.1016/j.eururo.2016.07.015 · Cited by 57
Chandrasekaran, G., Hwang, E. C., Kang, T. W., Kwon, D. D., Park, K., Lee, J., & Lakshmanan, V. (2017) · Scientific Reports · doi:10.1038/srep43830 · Cited by 54
Next-generation sequencing-based clinical sequencing: toward precision medicine in solid tumors
Wakai, T., Prasoon, P., Hirose, Y., Shimada, Y., Ichikawa, H., & Nagahashi, M. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-018-1375-3 · Cited by 50
Circulating steroid hormone variations throughout different stages of prostate cancer
Snaterse, G., Visser, J. A., Arlt, W., & Hofland, J. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0155 · Cited by 49
Complexity of Neural Component of Tumor Microenvironment in Prostate Cancer
Sejda, A., Sigorski, D., Gulczyński, J., Wesołowski, W., Kitlinska, J. B., & Iżycka‐Świeszewska, E. (2020) · Pathobiology · doi:10.1159/000505437 · Cited by 49
Arora, H., Panara, K., Kuchakulla, M., Kulandavelu, S., Burnstein, K. L., Schally, A. V., Hare, J. M., & Ramasamy, R. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1812704115 · Cited by 48
Transcriptional repression by androgen receptor: roles in castration-resistant prostate cancer
Yu, J., Gritsina, G., & Gao, W. (2019) · Asian Journal of Andrology · doi:10.4103/aja.aja_19_19 · Cited by 48
Yadav, S. S., Li, J., Lavery, H. J., Yadav, K. K., & Tewari, A. K. (2015) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2015.02.009 · Cited by 47
Testosterone therapy and cardiovascular diseases
Cittadini, A., Isidori, A. M., & Salzano, A. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab241 · Cited by 45
Development of PROSTVAC Immunotherapy in Prostate Cancer
Singh, P. P., Pal, S. K., Alex, A. B., & Agarwal, N. (2015) · Future Oncology · doi:10.2217/fon.15.120 · Cited by 44
Detecting selection signatures in three Iranian sheep breeds
Manzari, Z., Mehrabani-Yeganeh, H., Nejati‐Javaremi, A., Moradi, M. H., & Gholizadeh, M. (2019) · Animal Genetics · doi:10.1111/age.12772 · Cited by 44
Applications of Next-Generation Sequencing in Neoantigen Prediction and Cancer Vaccine Development
Lancaster, E. M., Jablons, D. M., & Kratz, J. R. (2019) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2018.0211 · Cited by 40
Verma, A. K., Tiwari, A., Lionetti, E., Srivastava, A., Monachesi, C., Catassi, G. N., Gatti, S., Galeazzi, T., & Catassi, C. (2021) · Foods · doi:10.3390/foods10102351 · Cited by 39
ELAC2 polymorphisms and prostate cancer risk: a meta-analysis based on 18 case–control studies
Xu, B., Tong, N., Li, J.-M., Zhang, Z.-D., & Wu, H.-F. (2010) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2010.6 · Cited by 38
Potential Applications of Nanotechnology in Urological Cancer
He, M., Chen, L., Zheng, T., Tu, Y., He, Q., Fu, H., Lin, J., Zhang, W., Shu, G., He, L., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00745 · Cited by 37
Lam, T., Birzniece, V., McLean, M. P., Gurney, H., Hayden, A. J., & Cheema, B. S. (2020) · Sports Medicine - Open · doi:10.1186/s40798-020-0242-8 · Cited by 36
Biomarkers for determination prostate cancer: implication for diagnosis and prognosis
Žiaran, S., Nováková, Z. V., Böhmer, D., & Danišovič, Ľ. (2015) · Neoplasma · doi:10.4149/neo_2015_082 · Cited by 34
Miura, Y., Kataoka, H., Joh, T., Tada, T., Asai, K., Nakanishi, M., Okada, N., & Okada, H. (2004) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2004.tb03491.x · Cited by 33
CRISPR Screen Contributes to Novel Target Discovery in Prostate Cancer
Tsujino, T., Komura, K., Inamoto, T., & Azuma, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312777 · Cited by 33
Prostate Cancer Genetics: A Review.
Wallis, C. J. D., & Nam, R. K. (2015) · PubMed Central · Cited by 31
Considering the potential for gene-based therapy in prostate cancer
Gregg, J. R., & Thompson, T. C. (2021) · Nature Reviews Urology · doi:10.1038/s41585-021-00431-x · Cited by 29
Gerritsen, W. R., & Sharma, P. (2011) · Journal of Clinical Immunology · doi:10.1007/s10875-011-9595-6 · Cited by 28
Molecular Basis of Drug Resistance and Insights for New Treatment Approaches in mCRPC
Giacinti, S., Poti, G., Roberto, M., Macrini, S., Bassanelli, M., Pietro, F. R. D., Aschelter, A. M., Ceribelli, A., Ruggeri, E. M., & Marchetti, P. (2018) · Anticancer Research · doi:10.21873/anticanres.12953 · Cited by 28
Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing
Bahmad, H. F., Demus, T., Moubarak, M. M., Daher, D., Moreno, J. C. A., Polit, F., López, O., Merhe, A., Abou-Kheir, W. G., Nieder, A. M., et al. (2022) · Medical Sciences · doi:10.3390/medsci10010015 · Cited by 28
Prognostic role of genetic biomarkers in clinical progression of prostate cancer
Álvarez-Cubero, M. J., Martínez-González, L. J., Saiz, M., et al. (2015) · Experimental & Molecular Medicine · doi:10.1038/emm.2015.43 · Cited by 27
HER2 gene amplification in patients with prostate cancer: Evaluating a CISH-based method
Sharifi, N., Salmaninejad, A., Ferdosi, S., Bajestani, A. N., Khaleghiyan, M., Estiar, M. A., Jamali, M., Nowroozi, M. R., & Shakoori, A. (2016) · Oncology Letters · doi:10.3892/ol.2016.5235 · Cited by 27
BRCA Mutation and Its Association With Colorectal Cancer
Soyano, A. E., Baldeo, C., & Kasi, P. M. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.06.006 · Cited by 27
Sirma, H., BROEMEL, M., Stumm, L., TSOURLAKIS, T., Steurer, S. A., Tennstedt, P., Salomon, G., Michl, U. H. G., Haese, A., Simon, R., et al. (2013) · Oncology Letters · doi:10.3892/ol.2013.1563 · Cited by 26
Xu, H., Kita, Y., Bang, U., Gee, P., & Hotta, A. (2021) · STAR Protocols · doi:10.1016/j.xpro.2021.100965 · Cited by 26
Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns
Mateo, L., Duran‐Frigola, M., Gris‐Oliver, A., Palafox, M., Scaltriti, M., Razavi, P., Chandarlapaty, S., Arribas, J., Bellet, M., Serra, V., et al. (2020) · Genome Medicine · doi:10.1186/s13073-020-00774-x · Cited by 25
Perspective on Precision Medicine in Oncology
Johnson, T. M. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1975 · Cited by 24
In touch with your feminine side: how oestrogen metabolism impacts prostate cancer
Rahman, H. P., Hofland, J., & Foster, P. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0118 · Cited by 23
Jiang, F., Liang, Y., Wei, W., Zou, C., Chen, G., Wan, Y., Liu, Z., Yang, Y., Han, Z., Zhu, J., et al. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11491 · Cited by 23
Circulating Tumor DNA: New Horizons for Improving Cancer Treatment
Lianos, G. D., Mangano, A., Cho, W. C. S., Dionigi, G., & Roukos, D. H. (2015) · Future Oncology · doi:10.2217/fon.14.250 · Cited by 22
8q24 allelic imbalance and MYC gene copy number in primary prostate cancer
Chen, H., Liu, W., Roberts, W., Hooker, S. E., Fedor, H. L., DeMarzo, A., Isaacs, W. B., & Kittles, R. A. (2010) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2010.20 · Cited by 21
Iguchi, T., Tamada, S., Kato, M., Yasuda, S., Machida, Y., Ohmachi, T., Ishii, K., Iwata, H., Yamamoto, S., Kanamaru, T., et al. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01554-3 · Cited by 19
Liquid biopsies reveal the dynamic nature of resistance mechanisms in solid tumors
Meador, C. B., & Lovly, C. M. (2015) · Nature Medicine · doi:10.1038/nm.3899 · Cited by 18
Evaluation of HOXB13 as a molecular marker of recurrent prostate cancer
JEONG, T.-O., Oh, K. J., NGUYEN, N. T. X., et al. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.769 · Cited by 18
Liu, Q., Tong, D., Liu, G., Yi, Y., Xu, J., Yang, X., Wang, L.-A., Zhang, J., Ye, J., Zhang, Y., et al. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1451278 · Cited by 18
Nishiyama, T. (2012) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2011.12.019 · Cited by 17
Iguchi, T., Tamada, S., Kato, M., Yasuda, S., Otoshi, T., Hamada, K., Yamasaki, T., & Nakatani, T. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01413-1 · Cited by 17
Prostate Cancer in 2021: Novelties in Prognostic and Therapeutic Biomarker Evaluation
Cimadamore, A., Roberta Mazzucchelli, A., Antonio Lopez-beltran, B., Massari, F., Santoni, M., Scarpelli, M., Liang Cheng, C., & Montironi, R. (2021) · Cancers · doi:10.3390/cancers13143471 · Cited by 17
Precision medicine applications in prostate cancer
McCrea, E. M., Lee, D. K., Sissung, T. M., & Figg, W. D. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918776920 · Cited by 16
Srivastava, M., Leighton, X., Starr, J. M., Eidelman, O., & Pollard, H. B. (2014) · BioMed Research International · doi:10.1155/2014/193635 · Cited by 11
Abstract 3302: The molecular landscape of oncogenic signaling pathways in The Cancer Genome Atlas
Sánchez-Vega, F., Mina, M., Armenia, J., Chatila, W. K., Luna, A., La, K., Dimitriadoy, S. G., Liu, D. L., Kantheti, H. S., Heins, Z. J., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-3302 · Cited by 9
Chlormadinone acetate is effective for hot flush during androgen deprivation therapy
Koike, H., Morikawa, Y., Matsui, H., Shibata, Y., Ito, K., & Suzuki, K. (2013) · Prostate International · doi:10.12954/pi.12010 · Cited by 5
Cited by
Wu, Z., Xia, F., & Lin, R. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01640-8 · Cited by 365
Iqbal, H., Inam‐Ur‐Raheem, M., Munir, S., Rabail, R., Kafeel, S., Shahid, A., Mousavi Khaneghah, A., & Aadil, R. M. (2024) · Food Science & Nutrition · doi:10.1002/fsn3.3869 · Cited by 19
Metadata
- Authors
- Sekhoacha, M., Riet, K., Motloung, P., Gumenku, L., Adegoke, A., & Mashele, S.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2022-09-05
- Volume
- 27
- Issue
- 17
- Pages
- 5730
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W4295080856
- Cited by
- 904
- References
- 168
- FWCI
- 103.17
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.